Literature DB >> 21253760

MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.

Kyoichi Kaira1, Haruyasu Murakami, Masakuni Serizawa, Yasuhiro Koh, Masato Abe, Yasuhisa Ohde, Toshiaki Takahashi, Haruhiko Kondo, Takashi Nakajima, Nobuyuki Yamamoto.   

Abstract

MUC1 is a transmembrane mucin that has been related to tumor progression and outcome in various malignancies. However, the clinical significance in thymic epithelial tumors remains unknown. We investigated the clinical significance of MUC1 expression in thymic epithelial tumors. Fifty-five patients with thymic epithelial tumors were included in this study. Tumors sections were stained by immunohistochemistry for MUC1, vascular endothelial growth factor (VEGF), microvessel density (MVD) determined by CD34, and p53. MUC1 were expressed in 29%. The expression of MUC1 was significantly correlated with the grade of malignancy in thymic epithelial tumors. MUC1 was closely associated with VEGF, p53 and MVD, and the overexpression of MUC1 was a prognostic marker for predicting poor outcome in univariate analysis. A positive rate of MUC1 expression was 94% (16/17) in thymic carcinomas and 0% (0/5) in type B3 thymomas, demonstrating a significant difference (p < 0.0001). The expression of MUC1 was closely related to the grade of malignancy in thymic epithelial tumors. A positive expression of MUC1 was significantly associated with poor outcome in this disease. MUC1 may be useful marker for differentiating thymic carcinoma from type B3 thymoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253760     DOI: 10.1007/s00428-011-1041-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

1.  MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage.

Authors: 
Journal:  Mol Urol       Date:  1999

2.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

Authors:  V Karanikas; L A Hwang; J Pearson; C S Ong; V Apostolopoulos; H Vaughan; P X Xing; G Jamieson; G Pietersz; B Tait; R Broadbent; G Thynne; I F McKenzie
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

3.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.

Authors:  S J Gendler; C A Lancaster; J Taylor-Papadimitriou; T Duhig; N Peat; J Burchell; L Pemberton; E N Lalani; D Wilson
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

4.  Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance.

Authors:  E Sivridis; A Giatromanolaki; M I Koukourakis; L Georgiou; P Anastasiadis
Journal:  Histopathology       Date:  2002-01       Impact factor: 5.087

5.  Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies.

Authors:  Eric A Engels; Ruth M Pfeiffer
Journal:  Int J Cancer       Date:  2003-07-01       Impact factor: 7.396

6.  Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas.

Authors:  Hong Feng; Mohammad Ghazizadeh; Hideki Konishi; Tsutomu Araki
Journal:  Jpn J Clin Oncol       Date:  2002-12       Impact factor: 3.019

7.  Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.

Authors:  Keiichi Kontani; Osamu Taguchi; Yoshitomo Ozaki; Jun Hanaoka; Satoru Sawai; Shuhei Inoue; Hajime Abe; Kazuyoshi Hanasawa; Shozo Fujino
Journal:  Int J Mol Med       Date:  2003-10       Impact factor: 4.101

8.  MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation.

Authors:  Joyce A Schroeder; Azzah Al Masri; Melissa C Adriance; Jennifer C Tessier; Kari L Kotlarczyk; Melissa C Thompson; Sandra J Gendler
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

9.  Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.

Authors:  Masakazu Kojika; Genichiro Ishii; Junji Yoshida; Mituyo Nishimura; Tomoyuki Hishida; Shu-ji Ota; Yukinori Murata; Kanji Nagai; Atsushi Ochiai
Journal:  Mod Pathol       Date:  2009-07-31       Impact factor: 7.842

10.  Increased expression of MUC1 in advanced pancreatic cancer.

Authors:  Yuji Hinoda; Yoshito Ikematsu; Michiko Horinochi; Shuji Sato; Kotaro Yamamoto; Tomoko Nakano; Mikiko Fukui; Yutaka Suehiro; Yuichiro Hamanaka; Yoshiro Nishikawa; Hideo Kida; Shinji Waki; Masaaki Oka; Kohzoh Imai; Suguru Yonezawa
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

View more
  12 in total

1.  Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.

Authors:  Mengying Yao; Weihong Zhang; Qingxian Zhang; Lihua Xing; Aiguo Xu; Qiuhong Liu; Bing Cui
Journal:  Lung       Date:  2011-10-01       Impact factor: 2.584

2.  Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.

Authors:  Xue-Ying Su; Wei-Ya Wang; Jin-Nan Li; Dian-Ying Liao; Wei-Lu Wu; Gan-Di Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Atypical thymomas with squamoid and spindle cell features: clinicopathologic, immunohistochemical and molecular genetic study of 120 cases with long-term follow-up.

Authors:  David I Suster; A Craig Mackinnon; Marcello DiStasio; Malay Kumar Basu; German Pihan; Saul Suster
Journal:  Mod Pathol       Date:  2022-02-10       Impact factor: 8.209

4.  Thymic carcinomas: clinicopathologic study of 37 cases from a single institution.

Authors:  Vincent Thomas de Montpréville; Maria-Rosa Ghigna; Ludovic Lacroix; Benjamin Besse; Philippe Broet; Philippe Dartevelle; Elie Fadel; Peter Dorfmuller
Journal:  Virchows Arch       Date:  2013-01-15       Impact factor: 4.064

5.  Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004.

Authors:  Lei Zhu; Jie Zhang; Alexander Marx; Christel Weiss; Wen-Tao Fang
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

6.  MUC1 downregulation inhibits non-small cell lung cancer progression in human cell lines.

Authors:  Tao Xu; Daowei Li; Hongmei Wang; Taohua Zheng; Guangqiang Wang; Ying Xin
Journal:  Exp Ther Med       Date:  2017-08-29       Impact factor: 2.447

Review 7.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

8.  MUC1 drives c-Met-dependent migration and scattering.

Authors:  Teresa M Horm; Benjamin G Bitler; Derrick M Broka; Jeanne M Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2012-11-27       Impact factor: 5.852

9.  MUC1 gene silencing inhibits proliferation, invasion, and migration while promoting apoptosis of oral squamous cell carcinoma cells.

Authors:  Ai-Min Zhang; Xiao-Hui Chi; Zu-Qiang Bo; Xiao-Fang Huang; Jin Zhang
Journal:  Biosci Rep       Date:  2019-09-16       Impact factor: 3.840

10.  Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery.

Authors:  Zhi-Gang Sun; Min Zhang; Fei Yang; Wei Gao; Zhou Wang; Liang-Ming Zhu
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.